Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 442.03% | -178.17% | -100.20% | -90.45% | -88.71% |
| Gross Profit | -442.03% | -97.89% | 100.20% | 90.45% | 88.71% |
| SG&A Expenses | 144.50% | -62.69% | 113.64% | 110.86% | -124.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 63.10% | -- | 97.75% | -480.00% | -- |
| Total Operating Expenses | 191.40% | -57.97% | 24.95% | 24.69% | -91.39% |
| Operating Income | -191.40% | -9.25% | -24.95% | -24.69% | 91.39% |
| Income Before Tax | 45.79% | -80.05% | -24.78% | -26.50% | -13.68% |
| Income Tax Expenses | -2,000.00% | -2,266.67% | -257.14% | 40.54% | 100.37% |
| Earnings from Continuing Operations | 46.08% | -79.25% | -24.69% | -26.66% | -19.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -74.51% | -66.67% | -83.33% | -67.74% | 1,800.00% |
| Net Income | 46.01% | -79.52% | -24.77% | -26.85% | -18.78% |
| EBIT | -191.40% | -9.25% | -24.95% | -24.69% | 91.39% |
| EBITDA | -336.68% | -16.58% | -22.78% | -21.86% | 94.44% |
| EPS Basic | 46.90% | -74.05% | -20.73% | -22.15% | -14.12% |
| Normalized Basic EPS | -410.95% | -11.82% | -20.89% | -22.39% | 95.34% |
| EPS Diluted | 46.90% | -71.43% | -20.73% | -22.50% | -13.62% |
| Normalized Diluted EPS | -410.95% | -11.82% | -20.89% | -22.39% | 95.34% |
| Average Basic Shares Outstanding | 1.69% | 3.15% | 3.34% | 3.85% | 4.07% |
| Average Diluted Shares Outstanding | 1.69% | 3.15% | 3.34% | 3.85% | 4.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |